...
机译:7岁时的结果为7年,黑色vs后移植后肾脏移植受者在福利福利和福利福利中施用Belatacept或环孢菌素 - ext ext
Recanati/Miller Transplant InstituteMount Sinai Medical CenterNew York NY USA;
Departments of Medicine and SurgeryUniversity of CaliforniaSan Francisco CA USA;
Department of NephrologyUniversity H?pital of BicêtreLe Kremlin‐Bicêtre France;
Department of SurgeryHenry Ford HospitalDetroit MI USA;
Department of NephrologyMedical College of WisconsinMilwaukee WI USA;
Renal and Pancreas Transplant DepartmentHospital Dom Vicente SchererPorto Alegre Brazil;
Department of MedicineGeorgia Regents UniversityAugusta GA USA;
Baylor University Medical CenterDallas TX USA;
Department of Nephrology and Organ TransplantationUniversity Hospital and INSERM U563Toulouse France;
Department of SurgeryPiedmont HospitalAtlanta GA USA;
Bristol‐Myers SquibbLawrenceville NJ USA;
Bristol‐Myers SquibbLawrenceville NJ USA;
Bristol‐Myers SquibbLawrenceville NJ USA;
Bristol‐Myers SquibbLawrenceville NJ USA;
Department of Internal MedicineHospital do RimS?o Paulo Brazil;
Department of SurgeryEmory University Transplant CenterAtlanta GA USA;
acute rejection; cadaver organ transplantation; clinical trial; kidney; kidney transplantation; renal function;
机译:7岁时的结果为7年,黑色vs后移植后肾脏移植受者在福利福利和福利福利中施用Belatacept或环孢菌素 - ext ext
机译:肾移植受者中基于Belatacept的方案与基于环孢素A的方案:BENEFIT和BENEFIT-EXT研究的2年结果。
机译:EBV加上3种试验(受益者和受益者除外)的降级肾脏肾脏接受者3年比较的结果
机译:实现器官移植中信息技术的好处:综述
机译:前瞻性肾移植受者中他汀类药物的生存益处
机译:Belatacept与环孢素治疗的扩展标准供体肾脏接受者的长期结果:BENEFIT-EXT的最终结果一项III期随机研究
机译:BENEFIT-EXT的三年结果:扩展标准供体肾脏接受者中Belatacept与环孢菌素的III期研究
机译:Noridian Healthcare solutions,LLC低估了其医疗保险部门可分配的退休后福利成本,并且超出了其他部门的可追加的退休后福利成本,适用于2006年至2010年的日历年度